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Patients with X-linked lymphoproliferative (XLP) disease
due to deﬁciency in the adaptor molecule signaling lympho-
cytic activation molecule–associated protein (SAP) are highly
susceptible to one speciﬁc viral pathogen, the Epstein-Barr
virus (EBV). This susceptibility might result from impaired
CD8+ T-cell and natural killer cell responses to EBV infection
in these patients. We demonstrate that antibody blocking of
the SAP-dependent 2B4 receptor is sufﬁcient to induce XLP-
like aggravation of EBV disease in mice with reconstituted
human immune system components. CD8+ T cells require
2B4 for EBV-speciﬁc immune control, because 2B4 blockade
after CD8+ T-cell depletion did not further aggravate symp-
toms of EBV infection.
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X-linked lymphoproliferative disease (XLP) type 1 is caused by
loss-of-function mutations in the SH2D1A gene and results in
increased susceptibility to Epstein-Barr virus (EBV)–associated
conditions. Affected boys develop fulminant infectious mono-
nucleosis, hemophagocytic lymphohistiocytosis, dysgammaglo-
bulinemia, lymphoproliferative disorders, and malignant
lymphoma [1]. The function of the protein encoded by the
SH2D1A gene, the signaling lymphocytic activation molecule
(SLAM)–associated protein (SAP), has been studied to
understand the cause of this disease [2]. The cytoplasmic SAP
family of adaptors, including SAP and Ewing’s sarcoma activat-
ed transcript 2 in humans, interact with SLAM-related receptors
(ie, SLAM [CD150], 2B4 [CD244], CD84 [SLAMF5], natural
killer, T and B cell antigen [NTB-A; CD352; SLAMF6], Ly9
[CD229] and CD2-like receptor activating cytotoxic cells
[CD319; SLAMF7]), which are exclusively expressed on hemato-
poietic cells. SLAM receptors transmit activating signals on en-
countering their homotypic self-ligands, with the exception of
2B4, which interacts with its ligand CD48 (SLAMF2), a surface
molecule that is also restricted to the hematopoietic lineage.
These signals are transmitted via SAP by either coupling SLAM
family receptors to SAP-recruited activating signaling cascades
or hindering their association with inhibitory effectors [3]. In the
context of SAP deﬁciency and EBV infection, 2 of these receptors,
2B4 and NTB-A, have been demonstrated in vitro to be defective
in their signaling function [4–6]. CD8+ T and natural killer (NK)
cells from patients with XLP disease display inhibitory rather than
activating signaling after engagement of these receptors [4–6].
In female heterozygote carriers, EBV-speciﬁc CD8+ T cells
express only wild-type SAP from 1 X chromosome, whereas
CD8+ T cells speciﬁc for other viruses in the very same individ-
uals can also express mutant SAP and seem to have stochasti-
cally condensed their SAP-encoding X chromosomes [7].
Therefore, alteration of the signal transduction pathways of
SLAM receptors 2B4 and NTB-A in CD8+ T cells and NK
cells is thought to be mainly responsible for the increased sus-
ceptibility to EBV infection and its sequelae in patients with
XLP disease type 1. Studies investigating the direct contribution
of SAP-deﬁcient lymphocyte subsets to EBV control in vivo
have not been done. The feasibility of modeling EBV infection
in mice with reconstituted human immune system components
(HIS mice), mirroring key features of human disease, has been
recently described by our laboratory and others, with both
CD8+ T and NK cells being protective [8–10].Moreover, mono-
clonal and oligoclonal lymphoproliferative tumors of B-cell or-
igin develop in 15%–25% of EBV-infected HIS mice [9, 10].
This model system allowed us for the ﬁrst time to speciﬁcally
address manipulations of SAP-dependent receptor signaling
and its consequences for EBV infection in vivo.
MATERIALS AND METHODS
Mice and EBV
NOD/LtSz-scid IL2Rγnull (NOD-scid γc
−/− or NSG) mice were
used to generate HIS mice, as described elsewhere [10]. Brieﬂy,
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1–2 × 105 CD34+ cells derived from human fetal livers were in-
jected intrahepatically into irradiated newborn mice and used
3–4 month after reconstitution. Green ﬂuorescent protein
transgenic wild-type EBV (B95-8) was titrated on Raji cells to
calculate Raji infecting units. Mice were infected intraperitone-
ally with 1 × 105 Raji infecting units and followed up for 5–6
weeks. The EBV load was measured by means of TaqMan (Ap-
plied Biosystems) real-time polymerase chain reaction, as de-
scribed elsewhere [10]. All animal protocols were approved by
the cantonal veterinary ofﬁce of the canton of Zurich, Switzer-
land (protocol 148/2011). All studies involving human samples
were reviewed and approved by the cantonal ethical committee
of Zurich, Switzerland (protocol KEK-StV-Nr.19/08).
2B4 Blockade and CD8+ T-Cell Depletion
For blocking experiments, mice were treated intraperitoneally
with 2 µg of anti-2B4 antibody (clone CO54; immunoglobulin
[Ig] M; provided by A. M.), anti-NTB-A antibody (clone ON56;
IgG2a; provided by A. M.) or isotype controls in phosphate-
buffered saline on the day before infection with EBV and
every second day during the course of infection. CD8+ T cells
were depleted with 150 µg of monoclonal antibody against
human CD8 (clone OKT-8; Bio X Cell) via intraperitoneal in-
oculation for 3 consecutive days just before EBV infection and
every second day (50 µg) beginning 2 weeks after infection for
the duration of the experiment.
Flow Cytometry
Peripheral blood mononuclear cells were separated on Ficoll-
Paque gradients, preincubated with unlabeled anti-2B4 (clone
CO54; provided by A. M.) for 30 minutes on ice, or left untreated
and after washing stained with anti-CD56 (clone NCAM16.2; BD
Biosciences), anti-CD3 (clone UCHT1; BioLegend), and anti-2B4
(clone C1.7; BioLegend). Analysis was performed with a LSR
Figure 1. Human 2B4 signaling is involved in the protective immune response against Epstein-Barr virus (EBV) in mice with reconstituted human immune
system components. A, EBV load in spleens 6 weeks after EBV infection (n = 11). Horizontal bar represents geometric mean; viral loads were compared with
2-tailed Mann–Whitney U test. B, EBV load over time in peripheral blood in mice treated with blocking antibody to 2B4 or immunoglobulin (Ig) M isotype
every other day (n = 10–12 per time point). Results represent mean and standard error of the mean (SEM); *P < .01 (2-way analysis of variance [ANOVA] with
Bonferroni correction). C, Weight loss over time after EBV infection relative to day 0 (n = 15–16). Results represent mean and SEM; *P < .05 (2-way ANOVA
with Bonferroni correction). D, Frequency of tumors at death in mice treated with blocking antibody to 2B4 or IgM isotype (numbers in columns indicate mice
with tumor/total mice); data are composite data from 2 independent experiments.
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Fortessa cytometer (BD Biosciences), and ﬂow cytometric data
was analyzed with FlowJo software v9.8 (Tree Star).
Detection of Human Interferon γ
Human interferon (IFN) γ in serum from HIS mice was analyzed
with a human IFN-γ enzyme-linked immunosorbent assay kit
(Mabtech), in accordance with the manufacturer’s protocols.
Statistical Analysis
Mann–Whitney U test was used to compare viral loads, and
1- or 2-way analysis of variance was used to analyze differences
between groups, as indicated in the ﬁgure legends. Differences
were considered statistically signiﬁcant at P < .05.
RESULTS AND DISCUSSION
To determine the role of 2B4 and NTB-A in EBV infection in
HIS mice, we masked these receptors with speciﬁc blocking an-
tibodies. Treatment of HIS mice with anti–NTB-A antibody
(IgG), however, depleted receptor-carrying leukocytes (reduc-
tion by 50% of human CD45+ leukocytes), whereas anti-2B4
(IgM) treatment did not (data not shown). The antibody used
to block 2B4 has been well described for its in vitro blocking
activity [11, 12], and it efﬁciently masked 2B4, thereby showing
its speciﬁcity (Supplementary Figure 1A and 2B). The expres-
sion of the 2B4 receptor is highly up-regulated during EBV in-
fection in HIS mice [10], and blocking 2B4 in EBV-infected HIS
Figure 2. Blocking 2B4 in the absence of CD8+ T cells does not alter the course of Epstein-Barr virus (EBV) infection. A, EBV load in spleens at the end
point (5–6 weeks after infection; n = 11). Horizontal bar represents geometric mean; viral loads were compared with 2-tailed Mann–Whitney U test. B, EBV
load over time in peripheral blood in mice depleted of CD8+ T cells and either treated with blocking 2B4 antibody, or not (n = 12–15 per time point). Results
represent mean and standard error of the mean (SEM); NS, not signiﬁcant (2-way analysis of variance [ANOVA] with Bonferroni correction). C, Weight loss
over time after EBV infection relative to day 0 (n = 13–20). Results represent mean and SEM. *P < .05; †P < .001 (2-way ANOVA with Bonferroni correction).
D, Frequency of tumors at death in mice depleted of CD8+ T cells and either treated with blocking 2B4 antibody or not, (numbers in columns indicate of mice
with tumor/total mice); data are composite data from 2 independent experiments.
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mice led to decreased IFN-γ serum levels 4 weeks after infection
(Supplementary Figure 1C), consistent with previous in vitro
data showing that activation of 2B4 is sufﬁcient to induce
IFN-γ [4, 5]. This effect was abolished 6 weeks after infection
(Supplementary Figure 1D), when anti-2B4–treated mice
showed viral loads increased by almost 1 log in both spleen
and blood (Figure 1A and 1B).
The increase in IFN-γ at this point to levels similar to or even
higher than those in isotype-treated mice (Supplementary Fig-
ure 1D) might have been provoked by the concurrent higher
viral load and subsequently more severe immunopathology. Fur-
thermore, anti-2B4–treated mice showed signs of exacerbated
disease, as evidenced by weight loss (Figure 1C), and had more tu-
mors (Figure 1D) than control mice, demonstrating a crucial role
for 2B4 signaling in the protective immune response against EBV
in HIS mice. Thus, aspects of SAP-deﬁcient XLP disease (ie, im-
paired viral control and augmented tumorigenesis) can be mim-
icked in HIS mice by using 2B4 blockade during EBV infection.
NK cells accumulate during acute symptomatic EBV infec-
tion in humans [13, 14] and are protective against EBV in
HIS mice [10]. Likewise, CD8+ T cells execute antiviral and an-
titumor responses in EBV-infected HIS mice [8, 9]. To deter-
mine which of these lymphocyte populations requires 2B4
signaling, we depleted CD8+ T cells during the course of EBV
infection with and without additional 2B4 blockade. In the ab-
sence of CD8+ T cells, infected mice demonstrated high viral
loads and suffered from severe weight loss and high tumor bur-
den (Figure 2), conﬁrming previous data [8, 9].
Importantly, when we blocked the 2B4 receptor on top of de-
pleting CD8+ T cells, disease severity was identical to that in
CD8+ T-cell–depleted mice with intact 2B4 signaling capability
in terms of viral load, weight loss, and tumor incidence (Figure 2).
This suggests that activation of 2B4 signaling on NK cells is not
essential during EBV infection. Rather, our results demonstrate
that abrogated 2B4 signaling pathways in CD8+ T cells are
responsible for the aggravated symptoms observed in anti-2B4–
treated nondepletedmice (Figure 1). Therefore, our studies indicate
that CD8+ T cells are the critical effector cells, being responsible for
the impaired immune response to EBV in HIS mice.
This is in good agreement with the ﬁnding that somatic re-
version of mutated SAP occurs primarily in effector memory
CD8+ T cells in patients with XLP disease [15]. Although
5%–10% of these adaptive lymphocytes revert their mutated
SAP gene to become functional, this reversion is very rarely
seen in NK cells [15]. These reverted CD8+ T cells regained nor-
mal responses toward EBV-infected cells compared with SAP-
deﬁcient cells of the same host, and patients with SAP reversion
had a prolonged median survival [15].
These clinical data and our ﬁndings in EBV-infected HIS
mice imply that compromised CD8+ T-cell–mediated immune
control after SAP mutation is the critical immune deﬁcit of
XLP disease. Furthermore, these data suggest that infusion of
autologous CD8+ T cells with gene therapy–corrected SAP
should be explored in patients with XLP disease.
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